Teva sells its only manufacturing plant in Russia
Teva discovers sophisticated fakes of popular drug | Financial Times
World's biggest generic-drug empire created - ISRAEL21c
Anything but Generic: A map for Selling to Teva Pharmaceuticals
Teva to cut 14,000 jobs | Business | Chemistry World
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times
Teva halts production at sterile injectables plant to address FDA concerns | FiercePharma
Buffett buys $358 million stake in Teva - Axios
Israel's Teva Seeks to Acquire Drug Manufacturer Mylan for $40 Billion | Jewish & Israel News Algemeiner.com
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva recalls U.S.-made drugs following contamination fears | Pittsburgh Post-Gazette
Drug firm ruled liable in 6-month opioid trial
18. Teva Pharmaceutical Industries | FiercePharma
Teva Recalls Drug Vials, Shuts Facility Over Mold Concerns - TheStreet
Jerusalem, Israel. 21st Oct, 2019. The Teva Pharmaceutical logo is seen in English and Hebrew at their tablet production plant in Jerusalem, on Monday, October 21, 2019. The Israeli drug manufacturer Teva's
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ANJL4AXVTBOMDKS2X4DIJZXZAY.jpg "Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters")
Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters
Running out of time and money, CEO to prioritize getting Teva out of the hole | The Times of Israel
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
D&O market faces $600mn Teva Pharmaceuticals loss
3 Reasons Why Beaten-Up Teva Stock Could Have a Big 2020 | InvestorPlace
